Literature DB >> 8841440

Recent advances in multiple antigen peptides.

J P Tam1.   

Abstract

The goals for the development of multiple antigen peptides (MAP) are to provide a rational and unambiguous system to multimerize different types of synthetic peptide antigens and to attach immunomodulating molecules for targeting and delivery. These goals have been largely realized and new designs of MAPs now permit a broad range of immune responses including CTLs and mucosal IgAs. Furthermore, significant advances by the inventiveness of many laboratories have led to applications of MAPs for serodiagnostic and other biochemical uses including those for drug discovery. An important aspect to accomplish various goals of MAPs is chemistry. New methodologies using unprotected peptides as building blocks have been developed to accommodate new and sophisticated design of MAPs. This review is written based on the personal perspective of my laboratory and will focus on the recent progress in MAPs, together with the chemistry to achieve their synthesis.

Mesh:

Substances:

Year:  1996        PMID: 8841440     DOI: 10.1016/0022-1759(96)00066-x

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  15 in total

1.  Conformational and linear B-cell epitopes of Asp f 2, a major allergen of Aspergillus fumigatus, bind differently to immunoglobulin E antibody in the sera of allergic bronchopulmonary aspergillosis patients.

Authors:  B Banerjee; P A Greenberger; J N Fink; V P Kurup
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  p185, an immunodominant epitope, is an autoantigen mimotope.

Authors:  Sanjeev Kumar; John A Hinks; Joseph Maman; Chelliah T Ravirajan; Laurence H Pearl; David A Isenberg
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

3.  Development of a Bioconjugate Platform for Modifying the Immune Response of Autoreactive Cytotoxic T Lymphocytes Involved in Type 1 Diabetes.

Authors:  Neha Nandedkar-Kulkarni; Abhishek R Vartak; Steven J Sucheck; Katherine A Wall; Anthony Quinn; Michael P Morran; Marcia F McInerney
Journal:  Bioconjug Chem       Date:  2019-07-05       Impact factor: 4.774

4.  The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells.

Authors:  Susan Wilson; Brett Greer; John Hooper; Andries Zijlstra; Brian Walker; James Quigley; Susan Hawthorne
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

5.  A strategy for rational design of fully synthetic glycopeptide conjugate vaccines.

Authors:  P Chong; N Chan; A Kandil; B Tripet; O James; Y P Yang; S P Shi; M Klein
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

6.  Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).

Authors:  Zhong-Li Liao; Xu-Dong Tang; Mu-Han Lü; Yu-Yun Wu; Ya-Ling Cao; Dian-Chun Fang; Shi-Ming Yang; Hong Guo
Journal:  Cancer Sci       Date:  2012-09-28       Impact factor: 6.716

7.  MAP dendrimer elicits antibodies for detecting rat and mouse GH-binding proteins.

Authors:  Roberto M Aguilar; Frank J Talamantes; Juan J Bustamante; Jesus Muñoz; Lisa R Treviño; Andrew O Martinez; Luis S Haro
Journal:  J Pept Sci       Date:  2009-02       Impact factor: 1.905

8.  Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide.

Authors:  Carolina Cubillos; Beatriz G de la Torre; Annamaria Jakab; Giorgia Clementi; Eva Borrás; Juan Bárcena; David Andreu; Francisco Sobrino; Esther Blanco
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

9.  Synthesis and characterization of a high-affinity {alpha}v{beta}6-specific ligand for in vitro and in vivo applications.

Authors:  Shunzi Li; Michael J McGuire; Mai Lin; Ying-Horng Liu; Tsukasa Oyama; Xiankai Sun; Kathlynn C Brown
Journal:  Mol Cancer Ther       Date:  2009-05-12       Impact factor: 6.261

Review 10.  Recent progress on MHC-I epitope prediction in tumor immunotherapy.

Authors:  Xiangyi Wang; Zhaojin Yu; Wensi Liu; Haichao Tang; Dongxu Yi; Minjie Wei
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.